Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Employees - 3,
CEO - Dr. Michael Myers Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 2.33M
Altman ZScore(max is 10): -4.1, Piotroski Score(max is 10): 1, Working Capital: $10745072000, Total Assets: $15709338000, Retained Earnings: $-55165792000, EBIT: -9528650, Total Liabilities: $6504665000, Revenue: $0
- Current Price $0.26 - Analyst Target Price $4.48| Ticker | QNRX |
| Index | - |
| Curent Price | 0.26 |
| Change | -11.08% |
| Market Cap | 2.33M |
| Average Volume | 8.79M |
| Income | -9.01M |
| Sales | 0.00M |
| Book Value/Share | 1.03 |
| Cash/Share | 1.57 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 5 |
| Moving Avg 20days | -8.32% |
| Moving Avg 50days | -14.85% |
| Moving Avg 200days | -52.35% |
| Shares Outstanding | 8.95M |
| Earnings Date | Mar 13 BMO |
| Inst. Ownership | 17.28% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.25 |
| Price/Cash | 0.17 |
| Price/FCF | - |
| Quick Ratio | 3.57 |
| Current Ratio | 3.57 |
| Debt/Equity | 0.00 |
| Return on Assets | -64.61% |
| Return on Equity | -121.15% |
| Return on Investment | -97.85% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 43.89 |
| BETA(β) | 1.39 |
| From 52week Low | 22.92% |
| From 52week High | -83.43% |
| EPS | -2.34 |
| EPS next Year | -0.40 |
| EPS next Qtr | -0.20 |
| EPS this Year | 33.51% |
| EPS next 5 Year | - |
| EPS past 5 Year | -143.98% |
| Sales past 5 Year | 0.00% |
| EPS Y/Y | 42.26% |
| Sales Y/Y | - |
| EPS Q/Q | 83.19% |
| Sales Q/Q | - |
| Sales Surprise | - |
| EPS Surprise | 23.91% |
| ATR(14) | 0.05 |
| Perf Week | -8.74% |
| Perf Month | -19.72% |
| Perf Quarter | -60.03% |
| Perf Year | -70.61% |
| Perf YTD | -60.03% |
| Target Price | 4.48 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer